30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt Download PDF Post navigationPreviousPrevious post:New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseNextNext post:Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitRelated PostsAB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025Summary of the virtual conference held on October 16, 2025October 16, 2025AB Science webcast of October 16, 2025October 16, 2025AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025Revenues for the first half of 2025 and update on AB Science’s activitiesOctober 10, 2025AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
AB Science announces the successful completion of a 2.8 million euros private placementOctober 17, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939October 14, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial reportSeptember 30, 2025
